FDA approves Perrigo, Cobrek dermatitis drug

Ketoconazole approved for patients ages 12 years and older

ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs' Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.

Extina has annual sales of about $10 million, according to Perrigo.

Recommended stories

Login or Register to post a comment.